Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: A randomized, prospective, controlled multi-center trial

Neurourology and Urodynamics
Annette SchröderRaimund Stein

Abstract

To verify the efficacy, safety and tolerability of intravesical administration of 0.1% oxybutynin hydrochloride compared to its oral administration for treatment of neurogenic detrusor overactivity (NDO) in a randomized, prospective, controlled, open-label, multi-center trial in 35 adult patients. NDO was confirmed within the previous 24 months by urodynamic studies (UDS). Group 1 (n = 18) received 10 ml 0.1% oxybutynin hydrochloride intravesically three times per day and group 2 (n = 17) 5 mg oxybutynin hydrochloride orally three times per day for a period of 28 days. Primary efficacy criterion was the change in the maximum bladder capacity between the beginning of the study and after 4 weeks as assessed by UDS. Adverse drug reactions (ADR) were collected and an evaluation of anticholinergic effects was conducted. The increase in maximum bladder capacity was 117 ml with intravesical application (P = 0.0002) versus 18 ml with the oral application (P = 0.51). The difference was statistically significant (P = 0.0086). ADR were reported by 10 (55.6%) of patients with intravesical administration, and by 14 (82.4%) of patients with oral administration. Significant differences in favor of the intravesical application were observed in...Continue Reading

References

Jan 1, 1977·Pharmacology·G F Anderson, C M Fredericks
Nov 1, 1976·Urology·I M Thompson, R Lauvetz
Aug 1, 1992·The Journal of Urology·C A MassadF E Trigo-Rocha
Aug 1, 1984·Acta Pharmacologica Et Toxicologica·L AaltonenR Sellman
Dec 1, 1995·European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery ... [et Al] = Zeitschrift Für Kinderchirurgie·G BuyseP Casaer
Feb 22, 2002·Neurourology and Urodynamics·Paul AbramsUNKNOWN Standardisation Sub-committee of the International Continence Society
May 11, 2002·Scandinavian Journal of Urology and Nephrology·Kari LehtorantaTeuvo L J Tammela
Jan 27, 2006·Der Urologe. Ausg. A·J PannekM Goepel
Jul 22, 2008·The Journal of Urology·Luis Antonio GuerraMichael Leonard

❮ Previous
Next ❯

Citations

Jun 30, 2018·Current Neurology and Neuroscience Reports·Jure Tornic, Jalesh N Panicker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.